"Before turning the call over to Bob, let me briefly comment on the announcement we made earlier this week, regarding the acquisition of Prism Pharmaceuticals, a specialty pharmaceutical company that has developed and received FDA approval for multiple presentations of NEXTERONE, an antiarrhythmic agent, amiodarone IV [intravenous] including the first and only ready-to-use premixed IV formulation. Given that this drug is typically administered to patients and extremely time-sensitive in critical care situations, the benefits of a ready-to-use premixed IV form of NEXTERONE are clinically significant. For this reason, we believe this unique product satisfies unmet clinical need, offers an opportunity to expand the current market and also has potential for application in additional geographies outside the United States. This transaction demonstrates our intent of being more proactive on the business development front. It also exemplifies the types of opportunities that we'll pursue, those to complement our existing portfolio and expand our market-leading position; leverage our global footprint, channel or customer relationships; capitalize on our core scientific or manufacturing capabilities; and provide for low integration risk, which provides a higher confidence in achieving success."
"We're pleased that we were able to close the Prism deal recently. This is going to be a nice opportunity for us. NEXTERONE could be, I would say, globally somewhere in the range of $150 million, $200 million product at high margins."